Pro Medicus (ASX:PME) Rallies on $23m Maryland Contract. Is This the Dip Investors Should Be Buying?

Pro Medicus jumps on new US contract

Pro Medicus (ASX:PME) jumped more than 8% on Wednesday after sealing a five-year, A$23 million contract with the University of Maryland Medical System. The deal will roll out PME’s cloud-based Visage 7 imaging platform across a network of 11 hospitals and more than 150 care locations. Good news, clearly. But here is what makes it interesting for investors: the stock is still sitting more than 60% below its July 2025 all-time high of A$336. Contract wins keep coming, yet the share price has not recovered. So what is really going on, and does this gap represent an opportunity?

What are the Best ASX Healthcare Stocks to invest in right now?

Check our buy/sell tips

Why the Maryland Contract Matters More Than the Dollar Value

On the surface, A$23 million over five years looks small compared to Pro Medicus’ blockbuster deals. Trinity Health was worth A$330 million. UCHealth came in at A$170 million. So why does this one matter?
Because of how Pro Medicus actually makes its money. The company runs on a transaction-based model, which means revenue grows every time a scan is processed through the platform. That may sound technical, but the implication is straightforward. A large hospital network like the University of Maryland Medical System, which handles more than 100,000 patient admissions every year, has the potential to generate far more revenue over time than the headline figure suggests. The more scans, the more PME earns.

There is also a bigger picture here. Pro Medicus has penetrated roughly 10% of its addressable US market. Every new contract adds to its reputation inside the US hospital system, making the next win easier to secure. The growth runway is still very long.

The Bull Case. Nothing Is Actually Broken

The selloff from the July 2025 peak has been sharp, but the business itself looks healthy. Pro Medicus carries essentially no debt and holds approximately A$222 million in cash and investments. That is a very comfortable financial position.

Revenue for FY2025 came in at A$213 million, up around 32% on the prior year. Contract wins have not slowed down. In our view, the slide from the peak looks more like a valuation reset and a shift in market sentiment than any sign the underlying business is struggling. The long-term thesis appears intact.

The Investor’s Takeaway

The honest answer here depends on what kind of investor you are.
If you are comfortable with growth stocks that trade at premium valuations and you believe in the long-term US expansion story, the current price is considerably more appealing than it was 12 months ago. The business is executing, the pipeline is strong, and the US market is far from saturated.

If you are more value-focused and want a bigger margin of safety before committing, waiting makes sense. Watching for signs that revenue growth is holding steady rather than slowing would give you more confidence in the entry point. Either way, this is a company where the fundamentals still support the story. The question is simply one of price and patience.